Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication
Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile
SAN DIEGO and CALGARY, AB , July 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company's intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.
"We are no longer in the business of funding proof-of-concept studies," said Jared Kelly , Chief Executive Officer of Oncolytics. "We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology."
Results from two completed first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) trials demonstrate a strong and consistent efficacy signal showing extremely rare 2-year overall survival rates of 21.9% vs. 9.2% based on pooled data from over 100 patients across two studies evaluating pelareorep combined with a chemotherapy backbone. In addition, a best-in-class 62% objective response rate (ORR) was observed in a single-arm study of pelareorep in combination with a chemotherapy backbone and a checkpoint inhibitor in 13 evaluable patients. These results collectively represent promising efficacy for a therapeutic regimen that includes an immunotherapy in this difficult-to-treat cancer. Currently, there are no approved immunotherapies for first-line treatment of mPDAC.
Pelareorep's clinical activity in HR+/HER2- metastatic breast cancer – a large indication with continued significant unmet medical need and no currently approved immunotherapies – has been demonstrated in two randomized phase 2 studies, both of which showed a median overall survival (mOS) benefit of greater than 10 months compared to standard-of-care chemotherapy (IND.213 mOS: 21.0 vs. 10.8 months; BRACELET-1 mOS: not statistically reached; conservative estimate = 32.1 months vs. 18.2 months). In the randomized, controlled BRACELET-1 study, pelareorep combined with paclitaxel yielded a 12.1-month median progression-free survival (PFS) compared to 6.4 months in the paclitaxel alone control arm.
"Pelareorep represents a tipping point for immunotherapy in cold tumors," said Dr. Thomas Heineman , Chief Medical Officer of Oncolytics. "It is delivering consistent immunologic and clinical responses in multiple tumor types. Most impressively, pelareorep activates the immune system to produce clinical benefits in cancers that are typically unresponsive to immunotherapies like mPDAC and unresectable HR+/HER2- breast cancer, creating new oncology entry points for immune-based combination therapies."
Data from more than 1,100 patients enrolled in multiple studies across several tumor types affirm that pelareorep has a favorable, well-understood safety profile. The most common treatment-related adverse events (TRAEs) are "flu-like" symptoms, such as fever, chills, headache, fatigue, myalgia, cough, anorexia, nausea, diarrhea, or vomiting, and rarely resulted in clinically significant grade ≥3 TRAEs. Adverse events are typically transient and manageable with over-the-counter medications.
Pelareorep received Fast Track designations from the U.S. Food and Drug Administration (FDA) in 2017 for metastatic breast cancer and in 2022 for mPDAC in combination with chemotherapy and atezolizumab. In 2015, pelareorep also received Orphan Drug Designations from the FDA and European Medicines Agency (EMA) for the treatment of pancreatic cancer.
The Company released a new corporate presentation, available on its website, that provides detailed clinical and translational data.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep directly into registration-enabling trials; our plans to use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Energy Plug Technologies Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2025) - Energy Plug Technologies Corp. (CSE: PLUG) (OTCQB: PLGGF) (FSE: 6GQ) ("Energy Plug") announces the granting of an aggregate amount of 950,000 stock options of the Company (the "Stock Options") to consultants of the Company. The Stock Options are exercisable at a price of $0.15 per share and are valid for a term of five years. The Stock Options are granted and governed by the Company's Stock Option Plan, approved by shareholders at the Company's annual general meeting held on March 17, 2025. The Stock Options vest over a term of one to two years and are subject to a statutory hold period of four month and one day in accordance with Canadian securities laws. About Energy Plug Technologies Corp. Energy Plug Technologies Corp. is a Canadian leader in advanced energy storage solutions, serving residential, commercial, and utility-scale markets with an emphasis on cybersecurity, grid resilience, and Indigenous economic development. For more information, visit Media Contact: Energy Plug Technologies Corp. Paul Dickson, CEO info@ +1 (604) 283-1262 Forward-Looking Statements This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Energy Plug Technologies Corp.'s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CTV News
35 minutes ago
- CTV News
Trump says he will hit copper imports with 50 per cent tariffs
U.S. President Donald Trump says he will be announcing a 50 per cent tariff on copper imports, but hasn't said when it will take effect. WASHINGTON -- U.S. President Donald Trump said Tuesday he will impose a 50 per cent tariff on copper imports -- but hasn't said yet when it will take effect. 'Today we are doing copper,' Trump told reporters at a cabinet meeting. 'I believe the tariff on copper, we are going to make it 50 per cent.' The level of tariff was reiterated in the meeting by Commerce Secretary Howard Lutnick. But the president was not scheduled to sign any executive orders Tuesday to implement the duties. Data from Natural Resources Canada shows the United States accounted for 52 per cent of Canada's copper export value in 2023. Canada's total exports of copper and copper-based products that year were valued at $9.3 billion. It's estimated Canada has less than one per cent of global copper reserves and it ranked 12th in the world's 2023 copper production, behind other major producers like Chile, Peru, the Democratic Republic of Congo, China and the United States. After Trump's remarks, shares in mining company Freeport-McMoRan were up 4.6 per cent and the price of copper was up 8.7 per cent to $5.47 per pound. Markets have seen large swings for months due to Trump's on-and-off efforts to realign global trade through tariffs. The looming copper tariffs are a sign that Trump plans to go ahead with a list of sectoral levies beyond his current import taxes on steel, aluminum and automobiles. Citing national security concerns, Trump earlier this year launched investigations under Section 232 of the Trade Expansion Act of 1962 into multiple products, including copper and pharmaceuticals. Trump said he will soon announce duties on pharmaceuticals but suggested he would give manufacturers a year before introducing those tariffs. 'After that they're going to be tariffed if they have to bring the pharmaceuticals into the country, the drugs and other things, into the country,' Trump said. 'They're going to be tariffed at a very, very high rate, like 200 per cent.' The Section 232 tariffs are separate from Trump's massive global tariff regime, which he delayed Monday in order to give his administration more time for trade negotiations. Devastating U.S. duties against countries around the world were set to come into force Wednesday before Trump pushed back the deadline to Aug. 1. Canada was not targeted by those global tariffs and has committed to coming up with some sort of bilateral deal with the U.S. by July 21. The Prime Minister's Office said Monday it was still working toward that deadline. Meanwhile, Canada's Finance Minister Francois-Philippe Champagne sent letters to provinces, territories and the Federation of Canadian Municipalities on Tuesday calling on them to support domestic steel and aluminum industries through 'strategic procurement policies.' Ottawa last month introduced rules to limit federal procurement to using steel and aluminum from Canada and 'reliable trading partners,' among other measures. In Champagne's letter, posted on social media, the minister urged his counterparts in other levels of government to 'take meaningful steps to implement similar policies in your jurisdictions.' 'A co-ordinated approach across jurisdictions would send a strong signal of unity and reinforce Canada's resolve to secure fair treatment for our businesses and workers,' the letter said. -- With files from The Associated Press U.S. President Donald Trump said Tuesday he will impose a 50 per cent tariff on copper imports -- but hasn't said yet when it will take effect. 'Today we are doing copper,' Trump told reporters at a cabinet meeting. 'I believe the tariff on copper, we are going to make it 50 per cent.' The level of tariff was reiterated in the meeting by Commerce Secretary Howard Lutnick. But the president was not scheduled to sign any executive orders Tuesday to implement the duties. Data from Natural Resources Canada shows the United States accounted for 52 per cent of Canada's copper export value in 2023. Canada's total exports of copper and copper-based products that year were valued at $9.3 billion. It's estimated Canada has less than one per cent of global copper reserves and it ranked 12th in the world's 2023 copper production, behind other major producers like Chile, Peru, the Democratic Republic of Congo, China and the United States. After Trump's remarks, shares in mining company Freeport-McMoRan were up 4.6 per cent and the price of copper was up 8.7 per cent to $5.47 per pound. Markets have seen large swings for months due to Trump's on-and-off efforts to realign global trade through tariffs. The looming copper tariffs are a sign that Trump plans to go ahead with a list of sectoral levies beyond his current import taxes on steel, aluminum and automobiles. Citing national security concerns, Trump earlier this year launched investigations under Section 232 of the Trade Expansion Act of 1962 into multiple products, including copper and pharmaceuticals. Trump said he will soon announce duties on pharmaceuticals but suggested he would give manufacturers a year before introducing those tariffs. 'After that they're going to be tariffed if they have to bring the pharmaceuticals into the country, the drugs and other things, into the country,' Trump said. 'They're going to be tariffed at a very, very high rate, like 200 per cent.' The Section 232 tariffs are separate from Trump's massive global tariff regime, which he delayed Monday in order to give his administration more time for trade negotiations. Devastating U.S. duties against countries around the world were set to come into force Wednesday before Trump pushed back the deadline to Aug. 1. Canada was not targeted by those global tariffs and has committed to coming up with some sort of bilateral deal with the U.S. by July 21. The Prime Minister's Office said Monday it was still working toward that deadline. Meanwhile, Canada's Finance Minister Francois-Philippe Champagne sent letters to provinces, territories and the Federation of Canadian Municipalities on Tuesday calling on them to support domestic steel and aluminum industries through 'strategic procurement policies.' Ottawa last month introduced rules to limit federal procurement to using steel and aluminum from Canada and 'reliable trading partners,' among other measures. In Champagne's letter, posted on social media, the minister urged his counterparts in other levels of government to 'take meaningful steps to implement similar policies in your jurisdictions.' 'A co-ordinated approach across jurisdictions would send a strong signal of unity and reinforce Canada's resolve to secure fair treatment for our businesses and workers,' the letter said. -- With files from The Associated Press By Kelly Geraldine Malone, The Canadian Press This report by The Canadian Press was first published July 8, 2025
CTV News
36 minutes ago
- CTV News
Unions warn public service will be ‘bearing the brunt' of federal government's savings plan
A sign for the Public Service Alliance of Canada (PSAC) in Ottawa on March 25, 2025. (Peter Szperling/CTV News Ottawa) Unions representing federal workers say Canadians will bear the cost of expected cuts to the public service as Prime Minister Mark Carney's government prepares to tighten the belt and find savings in day-to-day operating costs. CTV News learned Monday that federal ministers have been asked to find 7.5 per cent savings for the 2026-27 fiscal year that begins on April 1, 2026 followed by 10 per cent in 2027-28 and 15 per cent in 2028-29 in an effort to find 'long-term savings,' a promise Carney made during the election campaign. 'I'm very concerned by this announcement. The prime minister promised caps and not cuts and it definitely feels like the public service workers are going to be bearing the brunt of this,' Sharon DeSousa, president of the Public Service Alliance of Canada (PSAC), told CTV News Ottawa on Tuesday. 'We need to be working together. The government needs to work with its workers and unions and not around them. I think there's a better approach then the same old lazy austerity measures.' PSAC and other unions received a briefing from the federal government on Tuesday outlining the expenditure review called by the federal government. DeSousa says she wished the government had consulted with workers and unions before announcing the measures, saying workers know where gaps and efficiencies can be found to cut costs. 'There's no obligation to consult, so once again, we have department heads making decisions and that's what worries me the most is that you're not consulting people with expertise that are actually doing the jobs,' she said. Carney has pledged a slate of spending measures aimed to boost affordability and defence. It includes a middle-class tax cut and a $9.3 billion to meet NATO's defence spending target of two per cent of GDP by this fiscal year. During the federal election, Carney had promised to find savings from 'increased government efficiency' with $6 billion in savings in 2026-27 and $13 billion a year in 2028-29. A report from the Canadian Centre for Policy Alternatives says $13 billion in savings will 'mostly be in personnel expenditures in non-defence departments,' amounting to a 24 per cent cut in government spending. It suggested Carney's election promises could bring about the 'worst cuts in modern history' to the federal public service. The move comes as the federal government prepares a 2025 budget set to be tabled this fall. Canadian Association of Professional Employees (CAPE) president Nathan Prier said arbitrary austerity measures' would undermine the workers who will carry out the government's wishes to build major nation-building projects. 'When governments make big promises to Canadians, public sector employees are the ones who deliver on them. And when ideological governments directly undermine their productivity, Canadians ultimately suffer the consequences,' Prier said in a statement. 'Mark Carney's current proposals are another rehash of the last Liberal government – arbitrary austerity measures completely disconnected from the question of who is going to deliver on his promises to Canadians.' Prier said the union is advocating for cost-cutting measures that don't 'attack' the federal workforce and seeks changes to 'bloated' management ranks, dependence on private contractors and reiterated a desire to reduce the public service's real estate footprint by allowing workers to work from home. A report from the C.D. Howe Institute released last week said it projects Canada's deficit could top $92 billion this fiscal year alone, in part due to the government's defence spending commitments. William Robson, who serves as the CEO of the C.D. Howe Institute, believes it's possible the government can make savings in its operating spending without degrading the quality of public services. 'When you look at a lot of things that the federal government does and you look at the increased in spending that occurred over the last decade and the increased in headcount over the last decade, its not obvious there's any direct connection between the costs of operating the federal government and the quality of the services that we're getting,' he said. Robson is calling on the government to make steeper cuts to program spending and reduce federal transfers to provinces. 'If you're going to have these very expensive traditional defence commitments, you need to either look at a source of revenue that isn't personal or corporate income taxes or you have to look at spending cuts,' Robson said. 'Something has to give.' Statistics released by the Treasury Board of Canada Secretariat in the spring show 357,965 people worked for the federal government as of March 31, down from 367,772 people in 2024. With files from CTV News Ottawa's Austin Lee and CTV's Stephanie Ha
